- $13.78m
- $12.15m
- $6.09m
- 90
- 78
- 53
- 86
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.42 | ||
| Price to Tang. Book | 6.42 | ||
| Price to Free Cashflow | 10.56 | ||
| Price to Sales | 2.27 | ||
| EV to EBITDA | 7.31 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 76.63% | ||
| Return on Equity | 63.4% | ||
| Operating Margin | 27.33% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 30.09 | 6.22 | 5.84 | 6.01 | 6.09 | n/a | n/a | -30.14% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | -39.02 | +4.29 | +74.84 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
PharmChem Inc. sells and distributes the PharmChek Sweat Patch Device (PharmChek). PharmChek is a system that uses sweat to detect the presence of illegal drugs. It consists of a transparent polyurethane outer covering, a small absorbent pad, and a release liner. A unique number is printed on the Sweat Patch for identification and anticounterfeiting purposes. PharmChek detects Marijuana, Cocaine, Opiates, Amphetamine, Methamphetamine, PCP, Fentanyl, Oxycodone, Oxymorphone, Hydrocodone, Hydromorphone, Benzodiazepines, Methadone, and Buprenorphine. Its products include PharmChek Overlay, PharmChek Analysis Panels, and PharmChek for the Workplace. The PharmChek Overlay is made of the same polyurethane film as the PharmChek Sweat Patch and can be used to extend the wear time of the PharmChek Sweat patch. The PharmChek Sweat Patch can be used for standard non-DOT drug policy screens that include follow up, return to work, fitness for duty, reasonable suspicion, and random testing.
Directors
- Richard Irwin CHM (69)
- Joseph Halligan CEO (63)
- David Lattanzio CFO (65)
- Neil Fortner VPR (53)
- Bryan Merryman VPR (51)
- Baburaj Parakkal VPR (41)
- Stephen Schorr DRC (62)
- Donald Stroben DRC (77)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 1st, 2000
- Public Since
- August 8th, 1991
- No. of Employees
- 170
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
Pink Sheets on Nasdaq- Shares in Issue
- 4,594,643
- Address
- 2411 E. Loop 820 N, FORT WORTH, 76118
- Web
- https://pharmchek.com/
- Phone
- +1 5032272950
- Auditors
- Whitley Penn LLP
Upcoming Events for PCHM
Similar to PCHM
4Cable TV International
Pink Sheets on Nasdaq
Abattis Bioceuticals
Pink Sheets on Nasdaq
Accelera Innovations
Pink Sheets on Nasdaq
Quantum Medical Transport
Pink Sheets on Nasdaq
Aesthetic Medical International Holdings
Pink Sheets on Nasdaq
FAQ
What is the PharmChem share price?
As of Today at 22:38 UTC, shares in PharmChem are trading at $3.00. This share price information is delayed by 15 minutes.
How has the PharmChem share price performed this year?
Shares in PharmChem last closed at $3.00 and the price had moved by +9.89% over the past 365 days. In terms of relative price strength the PharmChem share price has outperformed the S&P500 Index by +2.67% over the past year.
What are the analyst and broker recommendations for PharmChem?
There is no consensus recommendation for this security.
Find out moreWhat is the PharmChem dividend yield?
The PharmChem dividend yield is 8.33% based on the trailing twelve month period.
Does PharmChem pay a dividend?
Last year, PharmChem paid a total dividend of $0.25, and it currently has a trailing dividend yield of 8.33%. We do not have any data on when PharmChem is to next pay dividends.
When does PharmChem next pay dividends?
We do not have data on when PharmChem is to next pay dividends. The historic dividend yield on PharmChem shares is currently 8.33%.
How do I buy PharmChem shares?
To buy shares in PharmChem you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of PharmChem?
As of the previous close price of $3.00, shares in PharmChem had a market capitalisation of $13.78m.
Where are PharmChem shares listed?
Here are the trading details for PharmChem:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: PCHM
What kind of share is PharmChem?
Based on an overall assessment of its quality, value and momentum PharmChem is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a PharmChem share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the PharmChem share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like PharmChem. Over the past six months, its share price has underperformed the S&P500 Index by -17.19%.
As of the last closing price of $3.00, shares in PharmChem were trading +3.17% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the PharmChem PE Ratio?
The PharmChem PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of PharmChem?
PharmChem's management team is headed by:
- Richard Irwin - CHM
- Joseph Halligan - CEO
- David Lattanzio - CFO
- Neil Fortner - VPR
- Bryan Merryman - VPR
- Baburaj Parakkal - VPR
- Stephen Schorr - DRC
- Donald Stroben - DRC